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An Illusion or a True Key to Successful
Ablation of Atrial Fibrillation?We read with great interest the article by Kottkamp
et al. (1). We agree that atrial ﬁbrosis may play an
important role in the maintenance of atrial ﬁbrillation
(AF). However, we would like to stress a few points
that seem to us important.
First, causal relationship between atrial ﬁbrosis
and AF has not been clearly conﬁrmed. In fact, recent
evidence indicates that while the atrial ﬁbrosis
naturally accompanies structural heart disease it is
not directly linked to AF per se (2). There is also no
direct evidence that AF can promote atrial ﬁbrosis in
humans. Clearly, the pathophysiology of AF extends
far beyond the mere concept of atrial ﬁbrosis.
Second, although magnetic resonance imaging
with late gadolinium enhancement (LGE) has been
extensively validated for visualization of a distinct
post-infarction scar in the left ventricle, thetechnique has not been histologically validated for
detection of predominantly diffuse pre-ablation
ﬁbrosis in the atria by any systematic study in
humans or in an animal experiment. Similarly, there
is no histological proof that low endocardial voltage
in the atria reﬂects solely ﬁbrosis. Therefore, we
believe that neither low endocardial voltage nor the
LGE may be interpreted as atrial ﬁbrosis without
precautious.
Our own data show no correlation between the
extent of pre-ablation left atrial LGE and other
characteristics of the atrial remodeling such as
volume, phasic function, or bipolar voltage. Most
importantly, in our experience the extent of left
atrial LGE does not predict AF recurrence after
ablation (3).
Thus, we feel that more solid experimental and
clinical evidence is needed before clinical application
of the proposed approaches to ablation of AF that are
based on visualization and modiﬁcation of the pre-
sumed “atrial ﬁbrosis.”*Marek Sramko, MD, PhD
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An Illusion or a True Key to Successful Ablation of
Atrial Fibrillation?We thank Drs. Sramko and Kautzner for their interest
in our manuscript (1). The success rates of current
stepwise ablation approaches adding the placement
Letters J A C C V O L . 6 5 , N O . 2 2 , 2 0 1 5
J U N E 9 , 2 0 1 5 : 2 4 6 2 – 8
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ablation after pulmonary vein (PV) isolation are
disappointingly low and indicate the need for new
substrate-targeted ablation strategies for atrial ﬁbril-
lation (AF) therapy.
Drs. Sramko and Kautzner commented on the
complex pathophysiology of AF. In fact, there is
general agreement about the complexity of the roles
of triggers (especially but not exclusively from the
PVs), of the substrate (including atrial ﬁbrosis), and of
a variety of modulators/modiﬁers (including hyper-
tension, obesity, and other cardiac risk factors, but
also inﬂammation, cancer, and other conditions). We
have analyzed data from intraoperatively obtained
specimen, post-mortem autopsy ﬁndings, electro-
anatomic voltage mapping (EAVM) studies, and
delayed enhancement (DE) magnetic resonance im-
aging (MRI) investigations, all of them supporting the
role of atrial ﬁbrosis for the human AF substrate, but
questioning “traditional wisdom” such as AF begets
AF and also the etiological role of age (2,3). Recently,
atrial ﬁbrosis was described to appear to be “a com-
mon endpoint of a wide range of AF-promoting con-
ditions” (4).
Drs. Sramko and Kautzner commented in addi-
tion on the role of DE MRI as well as EAVM as
imaging/mapping techniques or surrogates for atrial
ﬁbrosis. With respect to DE MRI, we have indicated
in our manuscript that “this modality requires
extensive MRI experience, and its reproducibility is
still under investigation in other groups” (1). In
general, new strategies and technologies that are
introduced into clinical practice always have limi-
tations. In order to appreciate the current limita-
tions of our proposed new techniques, we included
a “limitations” paragraph, which is indeed the
longest in our whole manuscript (1). However,
despite all limitations inherent to new techniques/
technologies, we see the future role for our pro-
posed strategies including the “box isolation of
ﬁbrotic areas,” and several clinical studies are
currently being performed already.
Overall, although it seems that we look from dif-
ferent angles, we indeed appreciate all comments
from Drs. Sramko and Kautzner because an open and
respectful discussion helps to further develop the
promising ﬁeld of substrate modiﬁcation in AF abla-
tion for our patients.*Hans Kottkamp, MD
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Complex Interplay of Anatomic,
Physiologic, and Outcome DataThe review by Arbab-Zadeh and Fuster advocates
for the assessment of atherosclerotic disease burden
as opposed to individual plaque vulnerability in
patients at risk for cardiac events. It also cites a
post hoc analysis of the COURAGE (Clinical Out-
comes Utilizing Revascularization and Aggressive
Drug Evaluation) trial, stating that angiographic
data (clearly not the optimal way to assess athero-
sclerotic burden) are superior to myocardial
ischemia testing in predicting outcome. So is the
predictive value of ischemia assessment simply a
reﬂection of atherosclerotic burden? The results of
combined studies for disease burden, ischemia, and
outcomes in different patient populations tend
mostly to disagree.
A study by Schenker et al. (1) evaluated 695
consecutive intermediate-risk patients undergoing
combined positron emission tomography perfusion
imaging and coronary calcium scoring. Patients with
ischemia carried a higher event rate at all levels of
coronary calcium. In another study of 541 patients
with suspected coronary disease undergoing coronary
computed tomography (CT) angiography and single-
photon emission computed tomography (SPECT)
myocardial perfusion imaging (MPI), anatomic and
functional information was synergistic (2). MPI in-
formation remained signiﬁcant in multivariate
models and the event rates between patients with
none or mild coronary stenosis and abnormal MPI and
